Insecticides (India) Limited has received a patent grant from the Patent Office, Government of India for its innovative insecticidal formulation. The company announced this development to stock exchanges under regulatory compliance requirements on March 31, 2026.

Patent Details

The granted patent covers a synergistic insecticidal combination of diafenthiuron and acetamiprid in wettable powder form, along with the process of preparing the same. This intellectual property protection represents a significant milestone for the company's research and development efforts in the agrochemical sector.

Regulatory Compliance

The company communicated this patent grant to both major Indian stock exchanges as part of its disclosure obligations. The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, which mandates companies to inform exchanges about material events and developments.

Strategic Significance

This patent grant provides Insecticides (India) Limited with exclusive rights to manufacture and market this specific synergistic combination for the duration of the patent term. The wettable powder formulation combining diafenthiuron and acetamiprid represents the company's innovation in developing effective pest control solutions for agricultural applications.

The 20-year patent protection period, calculated from the original filing date of July 23, 2013, ensures the company maintains competitive advantage in this particular formulation segment. Company Secretary and Chief Compliance Officer Sandeep Kumar signed the regulatory filing, confirming the receipt of this important intellectual property milestone.

Insecticides (India) Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, alongside declaring an interim dividend for shareholders. The agro-chemicals manufacturer's Board of Directors approved the results at their meeting held on January 30, 2026, followed by an earnings conference call to discuss performance and strategy.

Q3FY26 Financial Performance

The company's standalone performance for Q3FY26 showed mixed results compared to the previous year. Revenue from operations reached ₹38,356.38 lacs, representing a 6.78% increase from ₹35,922.71 lacs in Q3FY24. However, net profit declined to ₹884.30 lacs from ₹1,500.14 lacs in the corresponding quarter last year.

Nine Months Performance

For the nine months ended December 31, 2025, the company demonstrated resilient performance with revenue from operations of ₹1,71,618.51 lacs compared to ₹1,64,312.07 lacs in the corresponding period last year. Net profit for the nine-month period stood at ₹12,145.37 lacs versus ₹12,574.07 lacs in the previous year.

Management Commentary and Strategic Outlook

During the earnings conference call, Managing Director Rajesh Kumar Aggarwal highlighted that Q3 was marked by challenging operating conditions including weak farmer activities, cautious channel behavior, weather issues, and low pest incidence. Despite these headwinds, the company delivered 8% growth driven by proactive market engagement and strategic business decisions.

The management emphasized that growth during the quarter was volume-led rather than value-led, with B2B segment showing approximately 15% growth while B2C segment grew by 3-4%. The company faced sales returns of ₹50.00 crores in Q3, bringing total goods returns to approximately ₹200.00 crores for the year.

New Product Launches and Innovation

A key positive development was the strong traction from new product launches. SPARCLE, a broad-spectrum insecticide for brown planthopper control in rice, was successfully launched using advanced chemistry from Corteva. Other recent launches including Centran and Million also witnessed encouraging farmer response. The company launched 5 new products during the first 9 months and plans to launch another 5 products in the upcoming kharif season.

Interim Dividend Declaration

The Board declared an interim dividend of ₹2.00 per equity share, representing 20% on the face value of ₹10 per share for financial year 2025-26.

Future Outlook and Strategic Initiatives

The management expects Q4 to remain challenging with continued margin pressure due to higher base of last year. However, they outlined a clear growth revival roadmap targeting 8-10% sustainable growth over the next 2-3 years. Key strategic initiatives include capacity expansion at Dahej (expected operational by end of fiscal) and Sotanala formulation activities starting in next kharif season.

The company continues to focus on premiumization with 180-plus registrations across 22 countries for export growth. International subsidiary Kaeros achieved sales of approximately ₹90.00 crores in 9 months, on track to touch ₹100.00 crores for the full year.

Source: Earnings Conference Call Transcript